Acalabrutinib and Bortezomib for Blood Cancer Patients With Platelet Problems
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two medications (acalabrutinib and bortezomib) for patients with blood cancers who have developed immune reactions against blood transfusions, making it hard for their bodies to benefit from donated platelets. The study aims to see if this combination can help restore platelet transfusion effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (leukemia, lymphoma, or similar) and your body rejects platelet transfusions
- Your blood tests show high levels of HLA antibodies (immune proteins that cause transfusion rejection)
- You are between 18 and 65 years old
- You are in reasonably good health overall (able to perform light daily activities with minimal assistance)
- Your doctor believes you will live at least 6 months
- You have not had serious bleeding in your brain, lungs, or stomach, and are not taking drugs that damage platelets
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This trial tests how well platelet transfusions work for patients with blood cancers or bone marrow failure who have very low platelets and need a transfusion. It aims to see if the transfusions help control bleeding and improve outcomes.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.